Total pharma industry deals for January 2019 worth $94.21bn were announced, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 806.16% over the previous month and a rise of 372.53% when compared with the last 12-month average of $19.94bn.
In terms of number of deals, the sector saw no change over the last 12-month average with 132 deals against the average of 133 deals.
In value terms, North America led the activity with deals worth $92.7bn.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPharma industry deals in January 2019: Top 5 deals
The top five pharma deals accounted for 97.4% of the overall value in the sector globally during January 2019.
The combined value of the top five pharma deals stood at $91.77bn, against the overall value of $94.21bn recorded for the month. The top announced pharma deal tracked by GlobalData in January 2019 was Bristol-Myers Squibb‘s $82.83bn acquisition of Celgene.
In second place was Eli Lilly’s acquisition of Loxo Oncology for $8bn and in third place was Taiyo Holding’s $344.04m asset transaction with Daiichi Sankyo Propharma.
Acrotech Biopharma’s $300m asset transaction with Spectrum Pharmaceuticals and American International Group, Hercules Capital, Kohlberg Kravis Roberts & Co, Perceptive Advisors, Sequoia Capital Operations, Viking Global Investor’s venture financing of BridgeBio Pharma for $299.2m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to the GlobalData deals database.
